Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review outlines the main findings from clinical trials on teriflunomide's efficacy and safety for relapsing multiple sclerosis, noting clinical considerations and exploring its mechanisms based on various studies.

In this observational study, most patients with multiple sclerosis on teriflunomide who experienced hair thinning reported it as mild or moderate and largely recovered while continuing treatment.

This review discusses teriflunomide as a disease-modifying therapy for multiple sclerosis and highlights its effectiveness and safety in clinical trials, but reports no new clinical results.

This review of teriflunomide for relapsing-remitting multiple sclerosis examines its clinical and safety outcomes, finding it significantly reduces relapse rates and disability progression while being generally well-tolerated.

This review discusses the preclinical and clinical data on teriflunomide for multiple sclerosis, highlighting its selective action on immune cells without causing clinical immune suppression, and provides no new clinical results.

This study found that teriflunomide, an oral medication taken once daily, significantly slowed disability progression in patients with relapsing multiple sclerosis, supported by positive results in two Phase III trials and supplemented by various analyses including long-term studies and patient-reported outcomes.

This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.

This study concluded that psychological well-being and self-image among Filipino males with androgenetic alopecia may be influenced by age, education level, and disease severity.

This study found that collecting hair samples for cortisol analysis is feasible in community-dwelling individuals with longstanding multiple sclerosis, although no significant correlation between hair cortisol levels and perceived chronic stress was observed, highlighting the complexity of stress measurement in this population.

This article discusses the challenges of treating androgenetic alopecia due to limited approved medications, potential side effects, and unmet expectations and reports no new clinical results.

AGA patients have a lower quality of life than AA patients.

This article reviews the causes and current treatment options for androgenetic alopecia, reporting no new clinical findings and highlighting the need for more therapeutic choices.

Androgenetic alopecia (AGA) is a common, hereditary hair loss condition that can be slowed but not permanently reversed with available therapies.

This review highlights that alopecia areata significantly impacts mental health and finances, with patients facing depression, anxiety, and substantial out-of-pocket expenses due to limited insurance coverage.

This study found that people with androgenic alopecia, particularly women, are more prone to anxiety and depression, often adopting avoidant coping strategies, which are linked to emotional and psychological impacts rather than clinical severity.

This study suggests that androgenetic alopecia moderately affects quality of life, with women experiencing a higher impact and showing a greater willingness to pay for treatment than men.

This article discusses approaches to diagnosing and treating androgenetic alopecia but reports no new clinical results.

This review examines various conditions that resemble androgenetic alopecia, analyzing their pathogenesis and highlighting the difficulties they pose for accurate diagnosis and treatment; it reports no clinical results.

This study found that androgenetic alopecia significantly impairs quality of life among Nigerian patients, especially in areas like emotions, stigmatization, and self-confidence, highlighting the importance of psychosocial support.

This letter to the editor discusses patient perspectives on androgenetic alopecia treatment at a tertiary dermatology center in Singapore, though results or specific findings are not reported in the abstract.

In this study, several dermoscopic features such as hair diameter diversity, brown peripilar sign, and focal atrichia were frequently observed in both male and female androgenetic alopecia patients, highlighting these as potential AGA indicators.

This study found that college students with androgenetic alopecia exhibited higher levels of various psychological symptoms compared to those without AGA, with medical and art students showing particularly elevated symptoms.

This study explores the risk factors for androgenetic alopecia in women residing in Pasar Ambacang Sub-district, Padang City, emphasizing its potential impact on their quality of life and psychological well-being.

This study found that patients with androgenetic alopecia experience significantly higher symptoms of anxiety, depression, stress, and body image dissatisfaction compared to non-AGA controls, along with generally reduced self-esteem and life satisfaction.

This study reported that educating patients about androgenetic alopecia treatment options increased awareness of the ineffectiveness of hair cosmetics and their perceived cost.

This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This study concluded that heredity is associated with hair loss, while lifestyle and stress factors are not significantly related.

This article discusses various treatments for androgenetic alopecia and reports no new clinical results, noting the condition's aesthetic and psychological impact.

This study found that androgenetic alopecia negatively impacts the emotional and social well-being of Polish men, particularly younger individuals, with 66.7% reporting a significant effect on self-esteem.